Background Cellular cholesterol efflux is a key step in reverse cholesterol transport that may
impact on atherosclerotic cardiovascular risk. The process may be reliant on the availability …

Aim: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been identified as an
important regulator of low-density lipoprotein (LDL) receptor processing. Evolocumab and …

Aims Our comprehensive review highlights the drug development and pharmacogenomics
leading to the recent approval of PCSK9 inhibitors. We also review the anticipated future …

Background: Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin
type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipoprotein …

Background Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a
breakthrough in the treatment of hypercholesterolemia. The aim of this study was to perform …

The proprotein convertase subtilisin/kexin type 9 (PCSK9) gene and gain-of-function
mutations were first described in 2003. The gain-of-function mutations observed were …

Uncontrolled hyperlipidemia has been associated with serious cardiovascular events. Statin
use may not be optimal either due to low adherence or statin intolerance. Although the …

Importance Little is known about the heterogeneity in low-density lipoprotein cholesterol
levels (LDL-C) lowering with proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor …

Objective Hyperlipidemia is an important risk factor for atherosclerotic cardiovascular
disease. Many patients are intolerant to or have limited benefit from statins. Proprotein …

The approval of two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors,
evolocumab and alirocumab, in both Europe and the USA has provided clinicians with a …